Premium
Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl‐2 protein level in hormone‐refractory prostate cancer cells
Author(s) -
Karabulut B.,
Erten C.,
Gul M.K.,
Cengiz E.,
Karaca B.,
Kucukzeybek Y.,
Gorumlu G.,
Atmaca H.,
Uzunoglu S.,
Sanli U.A.,
Baran Y.,
Uslu R.
Publication year - 2009
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1016/j.cellbi.2008.11.011
Subject(s) - docetaxel , zoledronic acid , apoptosis , prostate cancer , cancer research , refractory (planetary science) , medicine , oncology , cancer , endocrinology , chemistry , biology , biochemistry , astrobiology
Docetaxel, a semi‐synthetic taxane analogue, is used effectively in the treatment of metastatic prostate cancer. Zoledronic acid, the most potent member of bisphosphonates, has shown pleiotropic anti‐tumoral effects on prostate cancer cells. We have explored the possible additive/synergistic effects and the apoptotic pathways induced by combination treatment of docetaxel and zoledronic acid in hormone and drug refractory, PC‐3 and DU‐145 prostate cancer cells. Combination of docetaxel and zoledronic acid synergistically inhibits cell growth in PC‐3 and DU‐145 cells. Moreover, this effect was due to downregulation of antiapoptotic protein Bcl‐2 in PC‐3 and DU‐145 cells. In conclusion, docetaxel/zoledronic acid combination is potentially a novel and effective approach for the treatment of prostate cancer.